Arthneeti
All Q4 FY25 results →
SA

Solara Active Pharma Sciences Ltd

Q4 FY25Pharmaceuticals & Biotechnology

Solara Active Pharma Sciences Q4 FY25 earnings call: Revenue & Margins

Q4 FY25 earnings call: what management guided on revenue, margins and order book.

Price₹617
Market cap₹2.4K Cr
P/E573.4
Updated23 Aug 2026
Read4 min read

The short version

The company expects a top-line revenue growth of around 10% for FY '26. The company expects a top-line revenue growth of around 10% in FY '26.

From Solara Active Pharma Sciences Ltd's Q4 FY25 earnings-call transcript · updated 23 Aug 2026.

Revenue & Sales Performance

  • The company expects a top-line revenue growth of around 10% for FY '26.
  • EBITDA is projected to grow by 15% to 20% in FY '26, driven by gross margin expansion and operating cost leverage.
  • Quarter-on-quarter sales growth is anticipated to start from Q1 FY '26.
  • The growth focus is on higher-margin products, especially ibuprofen derivatives and non-ibuprofen products, reducing reliance on plain ibuprofen.
  • Capacity utilization currently stands at 60%, indicating room for volume growth.

2 more points from Solara Active Pharma Sciences Ltd's call on revenue

Pro opens every point from 15K+ earnings calls

Profitability & Margins

See what Solara Active Pharma Sciences Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

  • The company has not yet started putting capital in the Vizag plant for onboarding customers. (Page 12)
  • There is small expected growth (10%-15%) from the Vizag plant, but onboarding customers is pending capital investment. (Page 12)
  • The company is building incremental capacities to debottleneck higher-margin products, indicating ongoing capacity expansions. (Page 5)
  • Discussions on capital investments related to the CDMO (CRAMS) business are underway, and more specifics will be shared closer to the scheme and NCLT process. (Page 10 and 13)

2 more points from Solara Active Pharma Sciences Ltd's call on capex

Pro opens every point from 15K+ earnings calls

Top-ranked in Pharmaceuticals & Biotechnology

Ranked on what management guided this quarter

Guidance-ranked
1KRM Ayurveda
Rev 1Mar 1
2Accretion Pha.
Rev 1Mar 2
3
Rev 1Mar 3
4
Rev 1Mar 3
5
Rev 1Mar 3
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what Solara Active Pharma Sciences Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

The transcript provided does not explicitly mention the current or expected order book or pending orders details for Solar Active Pharma Sciences Limited. However, some relevant points related to business outlook and operations are: - The company expects a top-line growth of around 10% in FY '26 with EBITDA growth between 15%-20%. - Capital investments at the Vizag plant have not yet started, so customer onboarding there has not begun, implying limited orders currently from that facility. - The company is focusing on growth in higher-margin products and shifting away from plain ibuprofen towards derivatives and non-ibuprofen products.

2 more points from Solara Active Pharma Sciences Ltd's call on order book

Pro opens every point from 15K+ earnings calls

Solara Active Pharma Sciences Ltd — Quarterly revenue & net profit

Revenue Net profit Net loss
Jun 2025Q1 FY26
Sep 2025Q2 FY26
Dec 2025Q3 FY26
Mar 2026Q4 FY26
Jun 2026Q1 FY27
Sep 2026Q2 FY27

Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹417 Cr, net profit ₹28 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Continue your research

What Solara Active's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

  • Jubilant Pharmo (Q4 FY25)

    Q4 FY25 consolidated revenue grew 10% YoY to Rs. Key concall takeaways from Jubilant Pharmova Ltd's Q4 FY25 earnings call — and how it ranks against sector…

  • Anuh Pharma Ltd (Q4 FY25)

    For Q4 FY 2025, operating revenue was ₹198.14 crore, a 2.24% year-on-year increase from ₹193.63 crore in Q4 FY 2024 (derived from annual total revenue…

  • Themis Medicare (Q4 FY25)

    71.70 Cr, down 27% YoY from Rs. Key concall takeaways from Themis Medicare Ltd's Q4 FY25 earnings call — and how it ranks against sector peers.

  • Lincoln Pharma. (Q4 FY25)

    Revenue: $1.2 billion, representing a 5% increase year-on-year. Key concall takeaways from Lincoln Pharmaceuticals Ltd's Q4 FY25 earnings call — and how it…

Compare:vs Sun Pharma.Inds.vs Divi's Lab.vs Torrent Pharmaceuticals Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Solara Active Pharma Sciences Ltd and 15K+ more earnings calls,
for less than your morning chai

a day

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Solara Active Pharma Sciences Ltd Q4 FY25 results?

The company expects a top-line revenue growth of around 10% for FY '26. The company expects a top-line revenue growth of around 10% in FY '26.

What is Solara Active Pharma Sciences Ltd share price analysis?

Solara Active Pharma Sciences Ltd currently shows a neutral. The stock trades at a P/E of 573.4 with a market cap of ₹2,448 Cr. Investors should review the full earnings analysis for detailed insights.

Is Solara Active Pharma Sciences Ltd planning capital expenditure?

The company has not yet started putting capital in the Vizag plant for onboarding customers.

Keep Solara Active Pharma Sciences Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.